Article
CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
Circulation. Cardiovascular genetics - 1 Oct 2013
Kim Ho-Sook, Chang Kiyuk, Koh Yoon-Seok, Park Mahn-Won, Choi Yun-Seok, Park Chul-Soo, Oh Minkyung, Kim Eun-Young, Shon Ji-Hong, Shin Jae-Gook, Seung Ki-Bae
Abstract excerpt
BACKGROUND: More intensive platelet suppression is required in patients with acute myocardial infarction (AMI) than in those with stable angina because of differential platelet activation between AMI and stable angina. In this context, CYP2C19 genotype leading to reduced active metabolite formation may profoundly affect the clinical outcome of clopidogrel therapy in patients with AMI compared with those with...
Topics
Join the communities discussing this publication.
